Saeed, A., Yothers, G., Puhalla, S. L., Rastogi, P., Freeman, T., Mathias, M. D., Seebach, F. A., Wolmark, N., George, T. J. (2026). NSABP FC-13 (EMPIRE): A phase II platform study of cemiplimab monotherapy or cemiplimab-based combinations in patients with colorectal cancer and minimal residual disease (MRD) after definitive therapy.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.tps3685